NCT Number: NCT00161889
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three treatment groups of Baxter study 205 (safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to 16 years).
Looking for future studies?
Notify MeKey information
Conditions
Age range
6 year–16 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Neuschwanstein Strasse 5, Augsburg, Germany
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All volunteers who participated in Baxter study 205 and received two vaccinations will be invited to participate. Male and female children will be eligible for participation in this study if:
- They received two vaccinations with one of the three different dosages of FSME IMMUN NEW during the course of Baxter study 205
- They and/or their legal guardian understand the nature of the study, agree to its provisions and give written informed consent
Exclusion criteria
There are no specific exclusion criteria for this study entry. However volunteers will be assessed for eligibility to receive a third vaccination.
Volunteers will be excluded from vaccination and consecutive visits in this study if they:
- Are not clinically healthy, (i. e. the physician would have reservations vaccinating with FSME IMMUN NEW outside the scope of a clinical trial)
- Have already been administered a third TBE vaccination elsewhere after the two vaccinations in Baxter study 205
- Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 205
- Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions
- Have received banked human blood or immunoglobulins within one month of study entry
- Are known to be HIV positive (a special HIV test is not required for the purpose of the study) since the last visit of Baxter study 205
- Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in Baxter study 205
- Had received an investigational new drug within 6 weeks prior to study start
- If female and capable of bearing children - have a positive pregnancy test at the first medical examination
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years
Important dates
- Study start
- 2002
- Study completion
- 2002
- First posted
- Sep 13, 2005
- Registry last updated
- May 21, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
NCT00840801
Arbovirus Infections, Brain Diseases
Eferding, Upper Austria, Austria
View Trial DetailsImmunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
NCT00460486
Arbovirus Infections, Brain Diseases
Krakow, Poland
View Trial DetailsTick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
NCT00894686
Arbovirus Infections, Brain Diseases
Oberösterreich, Austria
View Trial DetailsSafety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
NCT00161824
Arbovirus Infections, Brain Diseases
Dębica, Poland
View Trial Details